Investor Center Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors Read more about Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO Read more about Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO Bellicum Pharmaceuticals Appoints Atabak Mokari as Chief Financial Officer Read more about Bellicum Pharmaceuticals Appoints Atabak Mokari as Chief Financial Officer Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel Read more about Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant Read more about Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018 Read more about Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018 Bellicum Pharmaceuticals to Host Analyst and Investor Event and Webcast on Monday, December 3 Read more about Bellicum Pharmaceuticals to Host Analyst and Investor Event and Webcast on Monday, December 3 Bellicum Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference Read more about Bellicum Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference Bellicum Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update Read more about Bellicum Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update Bellicum Announces Data Presentations on Lead Product Candidate Rivo-cel and Controllable CAR Program at the 60th American Society of Hematology Annual Meeting Read more about Bellicum Announces Data Presentations on Lead Product Candidate Rivo-cel and Controllable CAR Program at the 60th American Society of Hematology Annual Meeting Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to
Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors Read more about Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors
Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO Read more about Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO
Bellicum Pharmaceuticals Appoints Atabak Mokari as Chief Financial Officer Read more about Bellicum Pharmaceuticals Appoints Atabak Mokari as Chief Financial Officer
Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel Read more about Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel
Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant Read more about Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant
Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018 Read more about Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018
Bellicum Pharmaceuticals to Host Analyst and Investor Event and Webcast on Monday, December 3 Read more about Bellicum Pharmaceuticals to Host Analyst and Investor Event and Webcast on Monday, December 3
Bellicum Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference Read more about Bellicum Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference
Bellicum Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update Read more about Bellicum Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Bellicum Announces Data Presentations on Lead Product Candidate Rivo-cel and Controllable CAR Program at the 60th American Society of Hematology Annual Meeting Read more about Bellicum Announces Data Presentations on Lead Product Candidate Rivo-cel and Controllable CAR Program at the 60th American Society of Hematology Annual Meeting
